Thyrocare Technologies Limited (THYROCARE) - Net Assets

Latest as of September 2025: Rs5.34 Billion INR ≈ $57.76 Million USD

Based on the latest financial reports, Thyrocare Technologies Limited (THYROCARE) has net assets worth Rs5.34 Billion INR (≈ $57.76 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs6.80 Billion ≈ $73.56 Million USD) and total liabilities (Rs1.46 Billion ≈ $15.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Thyrocare Technologies Limited to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs5.34 Billion
% of Total Assets	78.52%
Annual Growth Rate	16.11%
5-Year Change	28.03%
10-Year Change	49.63%
Growth Volatility	21.25

Thyrocare Technologies Limited - Net Assets Trend (2011–2025)

This chart illustrates how Thyrocare Technologies Limited's net assets have evolved over time, based on quarterly financial data. Also explore Thyrocare Technologies Limited asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Thyrocare Technologies Limited (2011–2025)

The table below shows the annual net assets of Thyrocare Technologies Limited from 2011 to 2025. For live valuation and market cap data, see THYROCARE stock market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs5.47 Billion ≈ $59.16 Million	+3.68%
2024-03-31	Rs5.28 Billion ≈ $57.06 Million	-1.42%
2023-03-31	Rs5.35 Billion ≈ $57.88 Million	+1.64%
2022-03-31	Rs5.27 Billion ≈ $56.95 Million	+23.24%
2021-03-31	Rs4.27 Billion ≈ $46.21 Million	+16.53%
2020-03-31	Rs3.67 Billion ≈ $39.65 Million	-15.73%
2019-03-31	Rs4.35 Billion ≈ $47.06 Million	-1.84%
2018-03-31	Rs4.43 Billion ≈ $47.94 Million	+8.97%
2017-03-31	Rs4.07 Billion ≈ $43.99 Million	+11.26%
2016-03-31	Rs3.66 Billion ≈ $39.54 Million	+17.68%
2015-03-31	Rs3.11 Billion ≈ $33.60 Million	+50.62%
2014-03-31	Rs2.06 Billion ≈ $22.31 Million	+28.83%
2013-03-31	Rs1.60 Billion ≈ $17.31 Million	+56.24%
2012-03-31	Rs1.02 Billion ≈ $11.08 Million	+51.74%
2011-03-31	Rs675.33 Million ≈ $7.30 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Thyrocare Technologies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1121.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs3.15 Billion	57.55%
Common Stock	Rs529.90 Million	9.69%
Other Comprehensive Income	Rs461.70 Million	8.44%
Other Components	Rs1.33 Billion	24.32%
Total Equity	Rs5.47 Billion	100.00%

Thyrocare Technologies Limited Competitors by Market Cap

The table below lists competitors of Thyrocare Technologies Limited ranked by their market capitalization.

Company	Market Cap
Limbach Holdings Inc NASDAQ:LMB	$837.88 Million
Jiangsu Rainbow Heavy Industries Co Ltd SHE:002483	$837.98 Million
Guangdong Mingzhu Group Co Ltd SHG:600382	$838.31 Million
Hektas Ticaret TAS IS:HEKTS	$838.32 Million
Life Healthcare JSE:LHC	$837.33 Million
Chongqing Pharscin Pharmaceutical Co Ltd SHE:002907	$837.17 Million
GMR Power and Urban Infra Limited NSE:GMRP&UI	$837.16 Million
SHANDONG HI-SP.G.HD-0001 F:HRI	$836.93 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Thyrocare Technologies Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,267,700,000 to 5,467,500,000, a change of 199,800,000 (3.8%).
Net income of 915,100,000 contributed positively to equity growth.
Dividend payments of 953,100,000 reduced retained earnings.
Share repurchases of 400,000 reduced equity.
New share issuances of 400,000 increased equity.
Other comprehensive income decreased equity by 341,900,000.
Other factors increased equity by 579,700,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs915.10 Million	+16.74%
Dividends Paid	Rs953.10 Million	-17.43%
Share Repurchases	Rs400.00K	-0.01%
Share Issuances	Rs400.00K	+0.01%
Other Comprehensive Income	Rs-341.90 Million	-6.25%
Other Changes	Rs579.70 Million	+10.6%
Total Change	Rs-	3.79%

Book Value vs Market Value Analysis

This analysis compares Thyrocare Technologies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.77x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 38.70x to 4.77x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-03-31	Rs12.57	Rs486.50	x
2012-03-31	Rs19.07	Rs486.50	x
2013-03-31	Rs36.66	Rs486.50	x
2014-03-31	Rs47.23	Rs486.50	x
2015-03-31	Rs55.50	Rs486.50	x
2016-03-31	Rs68.05	Rs486.50	x
2017-03-31	Rs75.79	Rs486.50	x
2018-03-31	Rs82.32	Rs486.50	x
2019-03-31	Rs81.32	Rs486.50	x
2020-03-31	Rs69.29	Rs486.50	x
2021-03-31	Rs80.69	Rs486.50	x
2022-03-31	Rs99.38	Rs486.50	x
2023-03-31	Rs100.79	Rs486.50	x
2024-03-31	Rs99.31	Rs486.50	x
2025-03-31	Rs102.05	Rs486.50	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Thyrocare Technologies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 16.74%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 13.31%
• Asset Turnover: 0.99x
• Equity Multiplier: 1.27x
Recent ROE (16.74%) is below the historical average (22.90%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	36.76%	32.64%	0.75x	1.49x	Rs180.72 Million
2012	34.10%	32.78%	0.78x	1.34x	Rs246.95 Million
2013	35.49%	42.32%	0.68x	1.23x	Rs408.08 Million
2014	22.38%	30.72%	0.61x	1.19x	Rs255.30 Million
2015	16.26%	24.40%	0.56x	1.20x	Rs171.83 Million
2016	14.17%	21.50%	0.59x	1.12x	Rs152.39 Million
2017	17.45%	23.13%	0.70x	1.07x	Rs302.87 Million
2018	21.04%	26.18%	0.74x	1.08x	Rs489.46 Million
2019	19.57%	21.13%	0.85x	1.09x	Rs416.28 Million
2020	24.11%	20.41%	0.92x	1.28x	Rs517.34 Million
2021	26.48%	22.88%	0.91x	1.28x	Rs704.22 Million
2022	33.45%	29.91%	0.97x	1.15x	Rs1.23 Billion
2023	12.07%	12.24%	0.83x	1.18x	Rs110.60 Million
2024	13.43%	12.37%	0.89x	1.22x	Rs180.83 Million
2025	16.74%	13.31%	0.99x	1.27x	Rs368.35 Million

Industry Comparison

This section compares Thyrocare Technologies Limited's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

Industry: Diagnostics & Research
Average net assets among peers: $4,532,172,005
Average return on equity (ROE) among peers: 11.11%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Thyrocare Technologies Limited (THYROCARE)	Rs5.34 Billion	36.76%	0.27x	$837.40 Million
Krsnaa Diagnostics Limited (KRSNAA)	$-228.96 Million	0.00%	0.00x	$210.31 Million
Dr. Lal Path Labs Ltd. (LALPATHLAB)	$5.10 Billion	25.94%	0.23x	$2.98 Billion
Metropolis Healthcare Limited (METROPOLIS)	$13.35 Billion	10.86%	0.40x	$308.02 Million
Syngene International Limited (SYNGENE)	$2.21 Billion	12.32%	1.28x	$1.99 Billion
Vijaya Diagnostic Centre Limited (VIJAYA)	$5.47 Billion	15.48%	0.56x	$1.42 Billion
Vimta Labs Limited (VIMTALABS)	$1.31 Billion	2.03%	0.39x	$247.25 Million

About Thyrocare Technologies Limited

NSE:THYROCARE India Diagnostics & Research

Market Cap

$837.40 Million

Rs77.43 Billion INR

Market Cap Rank

#10026 Global

#478 in India

Share Price

Rs486.50

Change (1 day)

+3.36%

52-Week Range

Rs349.55 - Rs1591.90

All Time High

Rs1591.90